Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer…
$89.08+0.30%
报价 2026-11-13
市值
$15.14B
EV
$15.55B
PE (TTM)
7.3x
预期 PE (FY2026)
12.3x
52 周区间距高点 -3.6%
$62.49$92.44
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 7.05 → 7.60(1.1x) | 11.7 |
| FY+32028-12 | 1.1x | 7.05 → 8.36(1.2x) | 10.7 |
毛利率 53% · TTM 收入 $8163M · 基数 EPS 7.05(调整后)
电话会信号
辅助标签Q3 20262026-11-05
上调指引
指引 上调
信心 4
分析师 4
“We are confident in the path ahead and the setup for significant value creation as RemainCo going forward.”
原文引用(1)
- 上调指引:we now expect earnings per share of $7.20 to $7.30 compared with our prior range of $7.10 to $7.20
蓝色标签在暴涨研究中略有区分度;悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SOLVSolventum Corporation | $15.14B | +0.3% | -0.0% | 53.5% | 7.3x | 5.5x | – | |
| RVTYRevvity, Inc. | $17.24B | -1.7% | +0.6% | 57.1% | 72.2x | 25.1x | 30.3x | |
| ICLRICON Public Limited Company | $14.58B | -2.9% | +1.6% | 19.6% | 34.7x | 13.4x | 12.2x | |
| EHCEncompass Health Corporation | $13.83B | +0.1% | +9.1% | 21.6% | 22.0x | 10.7x | 30.5x | |
| ELANElanco Animal Health Incorporated | $13.39B | +1.1% | +11.2% | 56.9% | – | 24.3x | 32.4x | GARP |
| RDYDr. Reddy's Laboratories Limited | $12.29B | +0.1% | – | 55.2% | 18.5x | 12.5x | – | |
| ALGNAlign Technology, Inc. | $11.86B | +0.8% | +2.6% | 68.7% | 25.0x | 14.9x | 20.1x | |
| ENSGThe Ensign Group, Inc. | $10.99B | +1.0% | +16.7% | 16.6% | 26.4x | 19.5x | 24.1x | |
| QGENQiagen N.V. | $10.3B | -0.4% | +2.9% | 63.6% | 25.8x | 16.0x | 23.2x | |
| 同行中位数 | – | – | +2.9% | 56% | 25.8x | 15.5x | 24.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。